Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Q32 Bio (QTTB) Current Deferred Revenue (2017 - 2023)

Q32 Bio (QTTB) has 7 years of Current Deferred Revenue data on record, last reported at $354000.0 in Q1 2023.

  • For Q1 2023, Current Deferred Revenue fell 88.97% year-over-year to $354000.0; the TTM value through Mar 2023 reached $354000.0, down 88.97%, while the annual FY2022 figure was $1.2 million, 63.97% down from the prior year.
  • Current Deferred Revenue reached $354000.0 in Q1 2023 per QTTB's latest filing, down from $1.2 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $5.6 million in Q4 2020 and bottomed at $354000.0 in Q1 2023.
  • Average Current Deferred Revenue over 5 years is $2.1 million, with a median of $1.3 million recorded in 2019.
  • Peak YoY movement for Current Deferred Revenue: soared 569.77% in 2021, then tumbled 88.97% in 2023.
  • A 5-year view of Current Deferred Revenue shows it stood at $1.3 million in 2019, then surged by 328.94% to $5.6 million in 2020, then plummeted by 43.04% to $3.2 million in 2021, then tumbled by 63.97% to $1.2 million in 2022, then crashed by 69.38% to $354000.0 in 2023.
  • Per Business Quant database, its latest 3 readings for Current Deferred Revenue were $354000.0 in Q1 2023, $1.2 million in Q4 2022, and $2.0 million in Q3 2022.